Table 1 Demographic characteristic of 270 eligible participants
All Study participants N = 270 (%) | New PTB patients N = 79 (%) | Previously treated PTB patients (N = 169) | Patients with unknown PTB history (N = 22) | a P-value | |
|---|---|---|---|---|---|
Variables | |||||
Age (y); mean SD | 37.7 ± 13.4 | 36.6 ± 14 | 38.0 ± 13.5 | 39.1 ± 10.7 | 0.271 |
Gender | 0.667 | ||||
Male | 179 (66) | 50 (63) | 113 (67) | 16 (73) | |
Female | 91 (34) | 29 (37) | 56 (33) | 6 (27) | |
Cities | <0.0001 | ||||
Bamenda | 14 (5) | 5 (6.3) | 9 (5.3) | 0 (0) | |
Douala | 133 (49) | 65 (82.3 | 47 (27.8) | 21 (95.5) | |
Yaounde | 123 (46) | 9 (11.4) | 113 (66.9 | 1 (4.5) | |
HIV status | 0.0008 | ||||
Positive | 63 (23) | 13 (16.5) | 50 (29.6) | 0 (0) | |
Negative | 140 (52) | 40 (50.6) | 96 (56.8) | 4 (18.2) | |
Unknown | 67 (25) | 26 (32.9) | 23 (13.6) | 18 (81.8) | |
Smear Status | 0.0012 | ||||
Smear negative | 44 (16) | 5 (6.3) | 38 (22.5) | 1 (4.5) | |
Smear positive | 226 (84) | 74 (93.7) | 131 (77.5) | 21 (95.5) | |
Grading of positive smears | |||||
Smear positive (AFB Scanty) | 17 (6) | 5 (6.8) | 10 (7.6) | 2 (9.1) | |
Smear positive (AFB 1+) | 17 (6) | 6 (8.1) | 8 (6.1) | 3 (13.6) | |
Smear positive (AFB 2+) | 46 (7) | 22 (29.7) | 22 (16.8) | 2 (9.1) | |
Smear positive (AFB 3+) | 146 (54) | 41 (55.4) | 91 (69.5) | 14 (63.6) | |
Phenotypic DST results | <0.0001 | ||||
Susceptible | 152 (56) | 53 (67.1) | 82 (48.5) | 17 (77.3) | |
Mono-drug resistant | 20 (7) | 7 (8.9 | 11 (6.5) | 2 (9.1) | |
Polydrug resistant | 5 (2) | 2 (2.5) | 2 (1.2) | 1 (4.5) | |
MDR | 49 (18) | 7 (8.9) | 42 (24.9) | 0 (0) | |
bNone | 44 (16) | 10 (12.7) | 32 (18.9) | 2 (9.1) | |